FIG. 02 / THE RESEARCH
PT-141 research: a central mechanism, a real trial base, and a contested margin of benefit.
Mechanism, the pivotal trials, the neuroimaging, and the critiques — organized by what each study measured.
Before the details
Here is the research in one breath. PT-141 turns on a brain receptor (MC4R) in the hypothalamus that helps drive sexual desire [1]. That was shown first in rats and monkeys, then in people [1][5]. Two large trials in women with low desire (RECONNECT) met their goals, and a year-long follow-up held [3][4]. Brain scans confirmed the effect runs through the brain, not blood flow [5].
The honest caveat: the desire gains are statistically real but small, and one meta-analysis found placebo did most of the work in this whole drug class [13]. PT-141 research is unusually deep for a peptide sold as a "research chemical" — but the depth is the approved women's indication. Everything else is thinner.
Mechanism: central, not vascular
PT-141 is an agonist at melanocortin receptors MC3R and MC4R, concentrated in the central nervous system [1]. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopamine pathways governing sexual desire [1]. In rats and nonhuman primates, systemic administration produced penile erections and activated hypothalamic neurons (increased c-Fos) — the signature of a central, not peripheral, action [1].
This is the key contrast with PDE-5 inhibitors, which act on vascular smooth muscle to improve blood flow. PT-141 does not act on the vasculature [7]. A 2022 fMRI study (n=31 premenopausal women with HSDD) gave mechanistic confirmation in humans: MC4R agonism raised desire for up to 24 hours and changed task-based brain processing of erotic stimuli, including enhanced amygdala-insula functional connectivity [5].
The pivotal trials
The RECONNECT program was two identical Phase 3 RCTs in 1,267 premenopausal women with HSDD [3]. The 1.75 mg subcutaneous as-needed dose met both coprimary endpoints: FSFI-desire +0.35 (P<.001) and FSDS-DAO item 13 −0.33 (P<.001) over 24 weeks, with nausea, flushing, and headache the most common adverse events [3].
The 52-week open-label extension followed 684 women. Efficacy was sustained, no new safety signals emerged, and the leading drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. A program-level safety synthesis confirmed the same tolerability profile across the development program [8]. An expert evaluation appraised the benefit-risk balance and therapeutic positioning relative to the few other options [9].
Preclinical and negative findings
In female rats, PT-141 selectively stimulated appetitive solicitational sexual behaviours without affecting lordosis, pacing, or general motor activity — implicating central melanocortin systems in female sexual desire and marking the first pharmacological agent reported to act on appetitive female sexual behaviour [2].
Not every model agreed. In female Syrian hamsters, melanocortin-receptor mRNA was concentrated in ventral-tegmental-area dopamine neurons, but neither low- nor high-dose bremelanotide changed that expression, and the peptide did not enhance sexual reward (conditioned place preference) — suggesting it does not act on the VTA-NAc reward circuit [6]. A negative finding is part of the record.
The contested margin
The benefit is real and small, and reasonable critics dispute its size. A meta-analysis of female-sexual-dysfunction trials found placebo accounted for roughly 67.7% of the measured effect, concluding current treatments are only minimally superior to placebo on the Female Sexual Function Index [13]. A pharmacotherapy review nonetheless judged the evidence for HSDD "good" while stressing that approved options remain few [14]. A separate review of female sexual dysfunction summarized efficacy and safety updates and a tiered process of care distinguishing pre- and postmenopausal women [11]. The honest reading: a measured effect, a contested magnitude, a narrow approved use.